News | July 15, 2022
Novavax statement on EMA Nuvaxovid label update related to allergic reaction
Novavax’ clinical development program reported no severe allergic reactions
Novavax’ clinical development program reported no severe allergic reactions
Proportion of the eligible population yet to receive a COVID-19 vaccine is comparatively small
Company is investing more than €100 million in the expansion of the Halle site
CEPI will provide seed funding of up to US$2.5 million to Codiak BioSciences.
Vaccizone’s ASC Technology is an enhanced antigen/bioactive delivery method based on Antigen Presenting Cells
The vaccine is under FDA review
The Government of Quebec, through its agent Investissement Quebec, is granting a loan of CAD 25 million
It is a two dose vaccine to be administered intramuscularly at 28 days apart
105 million 30 µg, 10 µg and 3 µg doses to be delivered into Q4 2022, with an option for the U.S. Government to purchase up to 195 million additional doses
States were also strongly advised to strictly monitor epidemiological profile of admitted COVID patients
Subscribe To Our Newsletter & Stay Updated
